Pfizer and Nektar reach agreement on Exubera

San Carlos-based Nektar Therapeutics (NKTR) has resolved a contract dispute with Pfizer Inc. (PFE) over its line of inhaled insulin products, the companies announced Tuesday.

Pfizer will pay Nektar $135 million to satisfy its obligations for contracts relating to Exubera, an inhaled insulin product, and agreed to transfer its remaining right to the product if Nektar finds another partner for its development and marketing, the compay said in a statement.

Pfizer announced it would discontinue Exhubera last month due to disappointing sales, taking a $2.8 billion charge in the third quarter as a result, according to the Associated Press.

The companies said they will continue to work together on PEGylated human growth hormone therapy for short stature and growth problems.

businessBusiness & Real Estate

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/
Previous story
College grads can count on accounting
Next story
Green light for park road closure

Just Posted

CAREN Act draws support from man who recorded viral Pac Heights video

The San Francisco man who recorded a viral video of a couple… Continue reading

Bay Area’s future could include a lot more remote work

Regional planning agency approved long-term work-from-home strategy to reduce emissions

Abundant Birth Project gives expecting mothers one less thing to worry about

Program aims to reduce Black, Pacific Islander preterm births with monthly payments, support

SFUSD reopening plan slowly taking shape

Six private schools among first to get waivers to resume in-person teaching

Police officers shot in protests after grand jury fails to indict officers for Breonna Taylor’s death

By Noah Goldberg, Leonard Greene and Nancy Dillon New York Daily News… Continue reading

Most Read